Neurocrine Biosciences (NBIX) Financial Analysis & Valuation | Quarter Chart
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs i... more
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endo... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $14.70B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Kyle W. Gano |
| IPO Date | 1996-05-23 | CAGR | 18.83% |
| Employees | 2,500 | Website | www.neurocrine.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 3.83% | Total Yield | 3.83% |
NBIX chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $15.02B | P/E | 21.13 | Forward P/E | 12.21 | PEG | 0.71 |
| P/S | 0.51 | P/B | 0.43 | P/CF | 1.93 | P/FCF | 1.96 |
| Sales | $3.37B | Sales 1Y | 34.42% | Sales 3Y | 101.67% | Sales 5Y | 226.96% |
| EPS | $6.92 | EPS 1Y | 101.78% | EPS 3Y | 294.22% | EPS 5Y | 83.33% |
| Sales QoQ | 17.74% | EPS QoQ | -27.23% | Sales QoQ Avg | 8.95% | EPS QoQ Avg | 16.71% |
| Gross Margin | 97.97% | Operating Margin | 23.34% | Profit Margin | 20.91% | ROCE | 17.56% |
| ROA | 13% | ROE | 21% | Altman Z Score | 8.83 | Piotroski Score | 5 |
| Current Ratio | 1.87 | Quick Ratio | 1.75 | Cash Ratio | 0.38 | Op. CF Ratio | 0.16 |
| Debt/Equity | 0.1 | Debt/Assets | 0.07 | Lt Debt/Equity | 0.1 | Lt Debt/Cap. | 0.09 |
| Intrst Cov. | -271.52 | Inventory Turnover | 0.66 | Asset Turnover | 0.63 | Receivables Turnover | 3.8 |
| Enterprise Value | $15.02B | P/E Ratio | 21.13 |
| Forward P/E | 12.21 | PEG Ratio | 0.71 |
| P/S Ratio | 0.51 | P/B Ratio | 0.43 |
| P/CF Ratio | 1.93 | P/FCF Ratio | 1.96 |
| EPS | $6.92 | EPS Growth 1Y | 101.78% |
| EPS Growth 3Y | 294.22% | EPS Growth 5Y | 83.33% |
| Revenue Growth 1Y | 34.42% | Gross Margin | 97.97% |
| Operating Margin | 23.34% | Profit Margin | 20.91% |
| ROE | 21% | ROA | 13% |
| ROCE | 17.56% | Current Ratio | 1.87 |
| Quick Ratio | 1.75 | Cash Ratio | 0.38 |
| Debt/Equity | 0.1 | Interest Coverage | -271.52 |
| Altman Z Score | 8.83 | Piotroski Score | 5 |
Neurocrine Biosciences (NBIX) valuation & financials
Neurocrine Biosciences (NBIX) has a market capitalization of $14.70B and trades at a price-to-earnings ratio of 21.1. It operates in the Healthcare sector (Biotechnology).
Neurocrine Biosciences's revenue grew +34.4% over the last year.
Neurocrine Biosciences's next earnings report is scheduled for October 27, 2026 after market close (provider scheduled date); analysts estimate EPS of $2.59. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)